Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Scher
    Scher
  2. Motzer
    Motzer
  3. Halpern
    Halpern
  4. Bajorin
    Bajorin
  5. D'Angelica
    D'Angelica
  6. Morris
    Morris
  7. Sheinfeld
    Sheinfeld
  8. Rosenberg
    Rosenberg
  9. Jarnagin
    Jarnagin
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (1254)
  2. Solid Tumor Oncology Division (776)
  3. Genitourinary Oncology Service (362)
  4. Division of Subspecialty Medicine (313)
  5. Survivorship Research (313)
  6. GSK Faculty (265)
  7. Hematologic Malignancies, Division of (259)
  8. Surgery (244)
  9. Center for Hematologic Malignancies (203)
  10. Population Sciences Research Program (203)
Search Within
  1. "Department of Medicine"
Formats
  1. Journal Article (821)
  2. Meeting Abstract (326)
  3. Review (35)
  4. Editorial (31)
  5. Correspondence (22)
  6. Guidelines (8)
  7. Research Letter (6)
  8. Conference Paper (5)
Groups
  1. Department of Medicine (1254)
  2. Solid Tumor Oncology Division (776)
  3. Genitourinary Oncology Service (362)
  4. Division of Subspecialty Medicine (313)
  5. Survivorship Research (313)
  6. GSK Faculty (265)

More Groups

People
  1. Howard Scher (118)
  2. Robert Motzer (105)
  3. Allan Halpern (58)
  4. Dean Bajorin (56)
  5. Joel Sheinfeld (33)
  6. Michael D'Angelica (33)

More People

Years
  1. 2024 (18)
  2. 2023 (75)
  3. 2022 (85)
  4. 2021 (85)
  5. 2020 (98)
  6. 2019 (75)

More Years

Publications
  1. Lancet Oncology (217)
  2. Journal of Investigative Dermatology (129)
  3. Journal of Urology (108)
  4. European Urology (104)
  5. Experimental Hematology (72)
  6. Journal of Molecular Diagnostics (70)

More Publications

Results (1254)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of early dexrazoxane use and cardiotoxicity risk in patients with soft tissue sarcoma treated with anthracyclines
    Meeting Abstract

    Jang, K.; Wallins, J. S.; Movva, S.; Tsay, A.; Liu, J. E.; Yu, A. F.
    Journal of the American College of Cardiology (2024)

    Fulltext@MSK | Save
  • Independent and incremental value of electrocardiographic markers for prediction of cancer therapy-related cardiac dysfunction
    Meeting Abstract

    Ibtida, I.; Ma, X.; Al-Sadawi, M.; Kosmidou, I.; Liu, J. E.; Okin, P. M.; Yu, A. F.
    Journal of the American College of Cardiology (2024)

    Fulltext@MSK | Save
  • Incremental utility of first-pass perfusion CMR for prognostic risk stratification of cancer-associated cardiac masses
    Journal Article

    Chan, A. T.; Maya, T. R.; Park, C.; Tak, K.; Liberman, N.; Jain, R. H.; Park, M. J.; Park, R. Y.; Grizzard, J.; Kim, G.; more...
    JACC: Cardiovascular Imaging (2024)

    Fulltext@MSK | Save
  • Safety analyses of the phase 3 VISION trial of [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Journal Article

    Chi, K. N.; Armstrong, A. J.; Krause, B. J.; Herrmann, K.; Rahbar, K.; de Bono, J. S.; Adra, N.; Garje, R.; Michalski, J. M.; Kempel, M. M.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    Journal Article

    Smit, E. F.; Felip, E.; Uprety, D.; Nagasaka, M.; Nakagawa, K.; Paz-Ares Rodríguez, L.; Pacheco, J. M.; Li, B. T.; Planchard, D.; Baik, C.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
    Review

    Browne, I. M.; André, F.; Chandarlapaty, S.; Carey, L. A.; Turner, N. C.
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): A phase 3, multicentre, open-label trial
    Journal Article

    Mahadeo, K. M.; Baiocchi, R.; Beitinjaneh, A.; Chaganti, S.; Choquet, S.; Dierickx, D.; Dinavahi, R.; Duan, X.; Gamelin, L.; Ghobadi, A.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study
    Journal Article

    Shitara, K.; Rha, S. Y.; Wyrwicz, L. S.; Oshima, T.; Karaseva, N.; Osipov, M.; Yasui, H.; Yabusaki, H.; Afanasyev, S.; Park, Y. K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save